<DOC>
	<DOC>NCT00857454</DOC>
	<brief_summary>Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-LotionÂ® (cutaneous solution) after completion of the MTE08 (NCT00702650) trial.</brief_summary>
	<brief_title>A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Hypogonadal males with a qualifying general medical health who have Completed the MTE08 trial up to and including Day 120/121 in a compliant manner Were able to communicate with the trial staff, understand the Trial Information Sheet and sign the Written Informed Consent Forms; were willing to follow the Protocol requirements and comply with Protocol restrictions and procedures Any clinically significant chronic illness or finding and/or laboratory testing that would interfere with the trial objectives or safety of the subject Any man in whom testosterone therapy was contraindicated, which included those with: Known or suspected carcinoma (or history of carcinoma) of the prostate or clinically significant symptoms of benign prostatic hyperplasia and/or clinically significant symptoms of lower urinary obstructions and with a International Prostate Symptoms Score (IPSS) score of greater than or equal to 19 Known or suspected carcinoma (or history of carcinoma) of the breast Severe liver disease (i.e. cirrhosis, hepatitis or liver tumours or liver function tests &gt;2 times the upper limit of the normal range values Active deep vein thrombosis, thromboembolic disorders or a documented history of these conditions Current significant cerebrovascular or coronary artery disease Untreated sleep apnoea Haematocrit of &gt;54% Untreated moderate to severe depression Men with clinically significant prostate exam or clinically significant elevated serum Prostate Specific Antigen (PSA) level (&gt; 4 ng/mL) or age adjusted reference range of PSA values Men taking concomitant medications (prescribed, overthecounter or complementary) that would affect Sex Hormone Binding Globulin (SHBG) or testosterone concentrations (excluding Testosterone MDLotion (cutaneous solution)) or metabolism such as warfarin, insulin, opiates, gonadotropinreleasing hormone analogues (GnRH), 5 alpha reductase inhibitors, propanolol, oxyphenbutazone, corticosteroids (except for physiological replacement doses), estradiol Men with uncontrolled diabetes (Hemoglobin A1c [HbA1c] greater than or equal to 10%) Subjects intending to have any surgical procedure during the course of the trial Subjects with a partner of child bearing potential who are not willing to use adequate contraception for the duration of the trial Subjects whose partners are pregnant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>